Skip to main content
SpringerLink
Log in

Orlistat

A Review of its Use in the Management of Patients with Obesity

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Orlistat is an inhibitor of gastrointestinal lipases and, therefore, prevents the absorption of dietary fat. This agent reduces weight in obese adults and adolescents with or without comorbidities (including type 2 diabetes mellitus, hypercholesterolaemia, hypertension, metabolic syndrome) who received up to 4 years of therapy in conjunction with a hypocaloric diet. In obese patients, orlistat in combination with a hypocaloric diet improved metabolic risk factors and reduced the risk of developing type 2 diabetes. Furthermore, this agent was cost effective in patients with obesity, particularly those with type 2 diabetes. Orlistat is generally well tolerated, with gastrointestinal adverse events being most commonly reported. Orlistat, in addition to lifestyle and dietary intervention, is thus an attractive option for the treatment of patients with obesity, especially those with associated comorbidities or at risk of developing type 2 diabetes.

Pharmacological Properties|

Orlistat potently and selectively inhibits gastric and pancreatic lipases, thereby preventing the hydrolysis of dietary fat. Consequently, the absorption of dietary fat is inhibited, with increased faecal fat excretion. This agent also decreases postprandial gastric acid secretion, gastric emptying and cholecystokinin release in response to a meal. Orlistat has a beneficial effect on several metabolic parameters, including plasma lipid levels, measurements of glycaemic control, blood pressure, plasma leptin and haemostatic factors. It is not associated with significant changes in fat-free mass or resting energy expenditure. Orlistat prevents weight loss-induced reductions in biliary composition.

Absorption of oral orlistat is minimal, with no evidence of accumulation after long-term administration. Orlistat is rapidly eliminated and excreted primarily in the faeces. With the exception of ciclosporin (cyclosporin), there are no clinically relevant drug interactions between orlistat and other commonly coadministered agents.

Therapeutic Use|

In obese patients treated with a mildly hypocaloric diet for the first year, bodyweight was reduced to a significantly greater extent with orlistat than placebo in large well designed trials (5–10% vs 2–7%).

In the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) trial (all patients received lifestyle and dietary intervention), the between-group difference in weight reduction was still significant after 4 years of treatment (5% vs 3%; p < 0.001). In this trial, orlistat also reduced the risk of developing type 2 diabetes by 37.3% compared with placebo; the risk reduction in patients with impaired glucose tolerance was 45%.

In obese patients with type 2 diabetes, weight reduction was significantly greater with up to 1 year's treatment with orlistat (4–6%) than with placebo (1–4%).

In obese and overweight adolescents, 1 year of orlistat treatment was significantly more effective than placebo in reducing body mass index, waist circumference and fat mass.

Orlistat improved aspects of quality of life to a significantly greater extent than placebo in obese patients.

Weight reduction of ≥5% after 12 weeks of orlistat treatment, but not weight reduction ≥2.5kg during a 4-week placebo plus hypocaloric diet lead-in period, was predictive of subsequent weight loss during long-term orlistat therapy.

Orlistat was significantly more effective than placebo in improving metabolic risk factors in obese patients with one or several comorbidities (including type 2 diabetes, hypercholesterolaemia, hypertension or metabolic syndrome). Generally, orlistat, compared with placebo, significantly improved levels of total cholesterol, low-density lipoprotein-cholesterol, glycosylated haemoglobin, fasting and postprandial insulin, fasting and postprandial glucose and systolic and/or diastolic blood pressure in these patients.

Orlistat was considered cost effective in the management of obese patients with type 2 diabetes, according to two long-term cost-effectiveness analyses. Incremental costs per event-free life year gained were €3462–19 986 (depending on level of complication) or $US8327.

Tolerability|

Orlistat was generally well tolerated in obese patients, with or without type 2 diabetes, in well controlled trials of up to 4 years' duration. The tolerability profile of orlistat in obese and overweight adolescents was similar to that in obese adults. Gastrointestinal adverse events were most commonly reported with orlistat therapy and were generally mild and transient. The incidence of mild-to-moderate hypoglycaemia was higher in obese patients with type 2 diabetes treated with orlistat than placebo; however, no patients required medical intervention. Decreases in plasma levels of fat-soluble vitamins occurred with orlistat therapy, although levels generally remained within the normal reference range.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Table V
Table VI
Table VII
Table VIII

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. World Health Organisation. Controlling the global obesity epidemic [online]. Available from URL: http://www.who.int/nut/obs.htm [Accessed 2004 Aug 16]

  2. Must A, Spandano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999; 282(16): 1523–9

    Article  PubMed  CAS  Google Scholar 

  3. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes 1997; 21 Suppl. 1: S5–9

    Google Scholar 

  4. Hauner H. Managing type 2 diabetes mellitus in patients with obesity. Treat Endocrinol 2004; 3(4): 223–32

    Article  PubMed  CAS  Google Scholar 

  5. Keating GM, Jarvis B. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Drugs 2001; 61(14): 2107–19; discussion 2120-1

    Article  PubMed  CAS  Google Scholar 

  6. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999 Oct; 58(4): 743–60

    Article  PubMed  CAS  Google Scholar 

  7. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3: S12–23

    CAS  Google Scholar 

  8. Borovicka J, Schwizer W, Guttmann G, et al. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut 2000 Jun; 46(6): 774–81

    Article  PubMed  CAS  Google Scholar 

  9. Shepard TY, Jensen DR, Blotner S, et al. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers. Int J Obes Relat Metab Disord 2000 Feb; 24: 187–94

    Article  PubMed  CAS  Google Scholar 

  10. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56(1): 82–5

    Article  PubMed  CAS  Google Scholar 

  11. Tan KC, Tso AW, Tam SC, et al. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 2002 Nov; 19(11): 944–8

    Article  PubMed  CAS  Google Scholar 

  12. Tong PC, Lee ZS, Sea MM, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002 Nov 25; 162(21): 2428–35

    Article  PubMed  CAS  Google Scholar 

  13. Tiikkainen M, Bergholm R, Rissanen A, et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004 Jan; 79(1): 22–30

    PubMed  CAS  Google Scholar 

  14. McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related comorbid conditions. J Pediatr Endocrinol Metab 2004 Mar; 17(3): 307–19

    Article  PubMed  CAS  Google Scholar 

  15. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002 Jul; 10(7): 642–50

    Article  PubMed  CAS  Google Scholar 

  16. Ozcelik O, Dogan H, Kelestimur H. Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: a 12-week, randomized, placebo-controlled study. Curr Ther Res Clin Exp 2004 Mar-Apr 30; 65(2): 127–37

    Article  CAS  Google Scholar 

  17. Rodrigues AM, Radominski RB, De Lacerda Suplicy H, et al. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J Clin Endocrinol Metab 2002 Apr; 87: 1621–6

    Article  PubMed  CAS  Google Scholar 

  18. Trouillot TE, Pace DG, McKinley C, et al. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol 2001 Jun; 96(6): 1888–94

    Article  PubMed  CAS  Google Scholar 

  19. Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 2000 Dec; 24(12): 1567–72

    Article  PubMed  CAS  Google Scholar 

  20. Chanoine J-P, Hauptman J, Boldrin M, et al. Beneficial effects on orlistat on weight and body composition in obese adolescents [abstract no. T7b:P7b-030 plus poster presented at the 13th European Congress on Obesity; 2004 May 26–29; Prague]. Int J Obes 2004; 28 Suppl. 1: 195

    Google Scholar 

  21. Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000 Mar; 24(3): 306–13

    Article  PubMed  CAS  Google Scholar 

  22. Mittendorfer B, Ostlund Jr RE, Patterson BW, et al. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001 Oct; 9(10): 599–604

    Article  PubMed  CAS  Google Scholar 

  23. Mathus-Vliegen EM, Van Ierland-Van Leeuwen ML, Terpstra A. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity. Aliment Pharmacol Ther 2004 Mar 1; 19(5): 601–11

    Article  PubMed  CAS  Google Scholar 

  24. Sari R, Balci MK, Coban E, et al. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes 2004 Aug; 28(8): 1059–63

    Article  CAS  Google Scholar 

  25. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143(3): 293–311

    Article  PubMed  CAS  Google Scholar 

  26. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in heathy volunteers. J Clin Pharmacol 1996; 36: 647–53

    PubMed  CAS  Google Scholar 

  27. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001 Aug; 25(8): 1154–60

    Article  PubMed  CAS  Google Scholar 

  28. Rissanen P, Vahtera E, Krusius T, et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001 Feb; 25: 212–8

    Article  PubMed  CAS  Google Scholar 

  29. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan; 27(1): 155–61

    Article  PubMed  CAS  Google Scholar 

  30. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39(1): 41–6

    Article  PubMed  CAS  Google Scholar 

  31. Roche Laboratories. Xenical® (orlistat): summary of product characteristics. Welwyn Garden City, Hertfordshire, UK: Roche, 2003

    Google Scholar 

  32. Roche Pharmaceuticals. Xenical® (orlistat) capsules: complete product information (US). Nutley (NJ): Roche Laboratories Inc., 2003

    Google Scholar 

  33. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995; 35: 1103–8

    PubMed  CAS  Google Scholar 

  34. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996; 36(11): 1006–11

    Article  PubMed  CAS  Google Scholar 

  35. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995; 35: 521–5

    PubMed  CAS  Google Scholar 

  36. Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 Sep; 42(9): 1011–9

    PubMed  CAS  Google Scholar 

  37. Oo CY, Akbari B, Lee S, et al. Effect of orlistat, a novel antiobesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia. Clin Drug Invest 1999; 17(3): 217–23

    Article  CAS  Google Scholar 

  38. Zhi J, Moore R, Kanitra L, et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol 2003 Apr; 43(4): 428–35

    Article  PubMed  CAS  Google Scholar 

  39. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996; 36: 654–8

    PubMed  CAS  Google Scholar 

  40. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tabletes (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996; 36: 352–5

    PubMed  CAS  Google Scholar 

  41. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995; 35: 840–3

    PubMed  CAS  Google Scholar 

  42. Hartmann D, Guzelhan C, Zuiderwijk PBM, et al. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996; 50: 421–4

    Article  PubMed  CAS  Google Scholar 

  43. Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998; 54: 773–7

    Article  PubMed  CAS  Google Scholar 

  44. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol 1996; 36: 152–9

    PubMed  CAS  Google Scholar 

  45. Errasti P, Garcia I, Lavilla J, et al. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc 2002 Feb; 34(1): 137–9

    Article  PubMed  CAS  Google Scholar 

  46. Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat. Am J Kidney Dis 2003 Feb; 41: 493–6

    Article  PubMed  Google Scholar 

  47. Barbara D, Orsini P, Pallini S, et al. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002 Mar–Apr 30; 8(2): 124–6

    Google Scholar 

  48. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov; 20(11): 2257–67

    Article  PubMed  CAS  Google Scholar 

  49. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002 Sep; 56(7): 494–9

    PubMed  CAS  Google Scholar 

  50. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000 Sep; 248(3): 245–54

    Article  PubMed  CAS  Google Scholar 

  51. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69: 1108–16

    PubMed  CAS  Google Scholar 

  52. Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003 May; 27(5): 591–7

    Article  PubMed  CAS  Google Scholar 

  53. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003 Apr 15; 91(8): 961–4

    Article  PubMed  CAS  Google Scholar 

  54. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281(3): 235–42

    Article  PubMed  CAS  Google Scholar 

  55. Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000 Feb; 9(2): 160–7

    Article  PubMed  CAS  Google Scholar 

  56. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res 2000 Jan; 8(1): 49–61

    Article  PubMed  CAS  Google Scholar 

  57. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 1998 Jul 18; 352(9123): 167–72

    Article  PubMed  CAS  Google Scholar 

  58. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21(8): 1288–94

    Article  PubMed  CAS  Google Scholar 

  59. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul; 25(7): 1123–8

    Article  PubMed  CAS  Google Scholar 

  60. Shi YF, Pan CY, Gao Y. Orlistat improves glycaemic control and weight loss in overweight and obese Chinese patients with newly diagnosed and previously untreated type 2 diabetes [abstract no. 691]. Diabetologia 2004; 47 Suppl. 1: A250

    Google Scholar 

  61. Guy-Grand B, Drouin P, Eschwege E, et al. Effects of orlistat on obesity-related diseases: a six-month randomized trial. Diabetes Obes Metab 2004 Sep; 6(5): 375–83

    Article  PubMed  CAS  Google Scholar 

  62. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 Nov; 4(6): 415–23

    Article  PubMed  CAS  Google Scholar 

  63. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25(6): 1033–41

    Article  PubMed  CAS  Google Scholar 

  64. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003 May; 5(3): 180–8

    Article  PubMed  CAS  Google Scholar 

  65. Erdmann J, Lippl F, Klose G, et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment: efficacy and limitations. Aliment Pharmacol Ther 2004 Jun 1; 19(11): 1173–9

    Article  PubMed  CAS  Google Scholar 

  66. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001 Nov; 25(11): 1713–21

    Article  PubMed  CAS  Google Scholar 

  67. Broom I, Hughes E, Dodson P, et al. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cardiol 2002; 9(8): 460–8

    Google Scholar 

  68. Bloch KV, Salles GF, Muxfeldt ES, et al. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens 2003 Nov; 21(11): 2159–65

    Article  PubMed  CAS  Google Scholar 

  69. Jacob S, Ziegler O, Toplak H, et al. Orlistat improves all components of the metabolic syndrome in overweight and obese patients on two diets [abstract no. T5P5b-011 plus poster presented at the 13th European Congress on Obesity; 2004 May 26–29; Prague]. Int J Obes 2004; 28 Suppl. 1: S154

    Google Scholar 

  70. Broom I, Lindgarde F, Guy-Grand B, et al. Weight loss at leadin is not a predictor for weight loss success with orlistat in patients with multimorbidities. Int J Obes 2004; 28 Suppl. 1: S152

    Article  Google Scholar 

  71. Rissanen A, Lean M, Rossner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003 Jan; 27(1): 103–9

    Article  PubMed  CAS  Google Scholar 

  72. Torgerson JS, Hauptman J, Boldrin M, et al. Efficacy of orlistat plus lifestyle changes in risk reduction of type 2 diabetes in obese patients with metabolic syndrome: a comparative analysis using National Cholesterol Education Program Adult Treatment Panel III vs European group for the study of insulin resistance criteria [abstract no. 690]. Diabetologia 2004; 47 Suppl. 1: A249

    Article  Google Scholar 

  73. Caterson I, Guy-Grand B, Hill J. Efficacy of orlistat in overweight and obese patients with metabolic syndrome [abstract plus poster presented at the 12th European Congress on Obesity; 2003 May 29–Jun 1; Helsinki]. Int J Obes Relat Metab Disord 2003 Sep 9; 27 (1139)

  74. Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002 Feb; 25(2): 303–8

    Article  PubMed  Google Scholar 

  75. Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21(7): 501–12

    Article  PubMed  Google Scholar 

  76. Clark Jr CM. The burden of chronic hyperglycemia. Diabetes Care 1998; 21 (12 Suppl.): C32–4

    Article  PubMed  Google Scholar 

  77. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53

    Article  Google Scholar 

  78. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–65

    Article  Google Scholar 

  79. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15(7): 820–5

    Article  PubMed  CAS  Google Scholar 

  80. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–12

    Article  PubMed  CAS  Google Scholar 

  81. Stevens RJ, Kothari V, Alder AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001; 101: 671–9

    Article  PubMed  CAS  Google Scholar 

  82. McEwan P, Jones M, Farine C, et al. Evaluation of the cost-utility of orlistat (Xenical) in the United Kingdom [abstract no. POB3]. Value Health 2004; 7(6): 721

    Article  Google Scholar 

  83. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 Jul; 22: 814–22

    Article  PubMed  CAS  Google Scholar 

  84. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003 Oct; 22(5): 357–62

    PubMed  CAS  Google Scholar 

  85. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–9

    Article  PubMed  Google Scholar 

  86. Martorell R, Khan LK, Hughes ML, et al. Obesity in women from developing countries. Eur J Clin Nutr 2000; 54: 247–52

    Article  PubMed  CAS  Google Scholar 

  87. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8(21 iii–iv): 1–182

    Google Scholar 

  88. Royal College of Physicians. Anti-obesity drugs: guidance on prescribing and management — a report of a working party of the Nutrition Committee of the Royal College of Physician [online]. Available from URL: http://www.rcplondon.ac.uk/pubs/wp_antiobesitydrugs.htm [Accessed 2004 Oct 26]

  89. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Arch Intern Med 1998 Sep 28; 158: 1855–67

    Article  Google Scholar 

  90. National Institute for Clinical Excellence. Guidance on the use of orlistat for the treatment of obesity in adults. Technology Appraisal Guidance 2001 Mar 12; (22): 10

    Google Scholar 

  91. Pisunyer FX, Becker DM, Bouchard C, et al. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. J Am Diet Assoc 1998 Oct; 98: 1178–91

    Article  Google Scholar 

  92. National Institute for Clinical Excellence. Guidance on the use of sibutramine for the treatment of obesity in adults. Technology Appraisal Guidance 2001 Oct 17; (31): 16

    Google Scholar 

  93. Hamilton M. Strategies for the management of patients with obesity. Treat Endocrinol 2002; 1(1): 21–36

    Article  PubMed  CAS  Google Scholar 

  94. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 2004: 89(6): 2616–21

    Article  PubMed  CAS  Google Scholar 

  95. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12(8): 1197–211

    Article  PubMed  CAS  Google Scholar 

  96. Prentice A, Jebb S, Blaskett A, et al. A patient support programme for orlistat: analysis of adherence and weight loss [abstract no. T5:O2-006]. Int J Obes 2004; 28 Suppl. 1: S28

    Google Scholar 

  97. Walker MD, Kolotkin R, Aultman R, et al. Evaluation of the impact of weight loss on quality of life in patients taking orlistat and enrolled in the motivation, advice and pro-active support (MAP) programme [abstract no. POB4]. Value Health 2004; 7 (6)

  98. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002 Jan; 4(1): 49–55

    Article  PubMed  CAS  Google Scholar 

  99. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165–75

    Google Scholar 

  100. Garrow J. Flushing away the fat. BMJ 1998; 317(7162): 830–1

    Article  PubMed  CAS  Google Scholar 

  101. Roche. More overweight people could benefit from weight loss drug Xenical® following recommendation from European Authorities [media release]. 2004

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 10, New Zealand

    Monique P. Curran & Lesley J. Scott

Authors
  1. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monique P. Curran.

Additional information

Various sections of the manuscript reviewed by: H.E. Bays, Louisville Metabolic and Atherosclerosis Research Center Inc., Louisville, Kentucky, USA; I. Broom, The Robert Gordon University, Aberdeen, Scotland; J.-P. Chanoine, Endocrinology and Diabetes Unit, British Columbia’s Children’s Hospital, Vancouver, British Columbia, Canada; B. Guy-Grand, Service de Nutrition, Hotel-Dieu, Paris, France; A Inui, Kobe University Graduate School of Medicine, Kobe, Japan; M. Krempf, Clinique d’Endocrinologie Nutrition, Hotel Dieu, Nantes, France; J. Wilding, University Hospital Aintree, Liverpool, England.

Data Selection

Sources: Medical literature published in any language since 1980 on orlistat, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were ‘orlistat’. EMBASE search terms were ‘orlistat’. AdisBase search terms were ‘orlistat’. Searches were last updated 5 November 2004.

Selection: Studies in patients with obesity who received orlistat. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Orlistat, obesity, type 2 diabetes mellitus, pharmacodynamics, pharmacokinetics, therapeutic use.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curran, M.P., Scott, L.J. Orlistat. Drugs 64, 2845–2864 (2004). https://doi.org/10.2165/00003495-200464240-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464240-00010

Keywords

Search

Navigation